Metastatic malignant melanoma

S. N. Markovic, L. A. Erickson, T. J. Flotte, L. A. Kottschade, R. R. Mcwilliams, J. W. Jakub, D. R. Farley, N. V. Tran, S. E. Schild, K. R. Olivier, S. Vuk-Pavlovic, A. Sekulic, R. H. Weenig, J. S. Pulido, J. F. Quevedo, R. G. Vile, G. A. Wiseman, I. Stoian, M. R. Pittelkow

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations


Metastatic malignant melanoma is an incurable malignancy with extremely poor prognosis. Patients bearing this diagnosis face a median survival time of approximately 9 months with a probability of surviving 5 years after initial presentation at less than 5%. This is contrasted by the curative nature of surgical resection of early melanoma detected in the skin. To date, no systemic therapy has consistently and predictably impacted the overall survival of patients with metastatic melanoma. However, in recent years, a resurgence of innovative diagnostic and therapeutic developments have broadened our understanding of the natural history of melanoma and identified rational therapeutic targets/strategies that seem poised to significantly change the clinical outcomes in these patients. Herein we review the state-of-the-art in metastatic melanoma diagnostics and therapeutics with particular emphasis on multidisciplinary clinical management.

Original languageEnglish (US)
Pages (from-to)1-26
Number of pages26
JournalGiornale Italiano di Dermatologia e Venereologia
Issue number1
StatePublished - Feb 2009


  • Melanoma, diagnosis
  • Metastases
  • Skin neoplasms

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Metastatic malignant melanoma'. Together they form a unique fingerprint.

Cite this